Dipartimento Medicina Clinica E Sperimentale, Sezione Di Endocrinologia, Università Di Pisa, Via Paradisa 2, 56124, Pisa, Italy.
Department of Obstetrics and Gynecology, University Hospital Pisa, Pisa, Italy.
J Ovarian Res. 2021 Jun 29;14(1):85. doi: 10.1186/s13048-021-00836-7.
Premature ovarian insufficiency (POI) is an ovarian defect characterized by primary or secondary amenorrhea, hypergonadotropism and hypoestrogenism which occurs before the age of 40 years with a major genetic component. In this study we performed clinical evaluation and genetic analysis of a group of 18 patients with POI. The study involved 18 consecutive women with POI. Karyotiping and genetic analysis for research of mutations in GDF9 (Growth Differentation Factor 9) and BMP15 (Bone morphogentic protein 15) genes and FMR1 (Fragile X Mental Retardation 1) premutation were carried out. In vitro functional study of the novel BMP15 mutation was performed using COV434 (Human ovarian granulosa tumour cells 434) cells of ovarian granulosa, which consistently express BMP responsive element, and luciferase reporter assay.
Three patients (17%) had a family history of POI. Ten patients (56%) had a family history of autoimmune diseases and nine patients (50%) showed a personal history of one or more autoimmune diseases. Of patients for whom morphological assessment was available, almost half (44%) had poor follicle assets or small ovaries's size at pelvic US. Two patients (13%) showed reduced bone density at DEXA (Dual Energy X-ray Absorptiometry). All the women had normal female kariotype and no mutations in the GDF-9 gene or FMR1 premutations were found. A novel heterozygous mutation c.406G > C (V136L) of BMP15 gene was identified in one patient. After transfection in COV434 cells, BMP15 variant showed a significantly reduced luciferase activity compared to wild type.
POI is a multifactorial disease with several health implications. Autoimmunity and genetics represent the most common aetiology. We identified and characterized a novel BMP15 mutation, providing an additional elucidation of molecular basis of this complex disorder.
卵巢早衰(POI)是一种卵巢缺陷,表现为原发性或继发性闭经、促性腺激素升高和雌激素水平降低,发生于 40 岁之前,主要与遗传因素有关。本研究对一组 18 例 POI 患者进行了临床评估和基因分析。该研究纳入了 18 例连续的 POI 女性患者。进行了核型分析和 GDF9(生长分化因子 9)和 BMP15(骨形态发生蛋白 15)基因突变以及 FMR1(脆性 X 智力低下 1)前突变的研究。使用卵巢颗粒细胞 COV434(Human ovarian granulosa tumour cells 434)细胞进行了新型 BMP15 突变的体外功能研究,该细胞持续表达 BMP 反应元件,并进行了荧光素酶报告基因检测。
3 例(17%)患者有 POI 家族史。10 例(56%)患者有自身免疫性疾病家族史,9 例(50%)患者有 1 种或多种自身免疫性疾病病史。对于可进行形态学评估的患者,近一半(44%)患者经盆腔 US 检查显示卵泡储备不良或卵巢体积小。2 例(13%)患者经 DEXA(双能 X 线吸收法)检查显示骨密度降低。所有女性均具有正常的女性核型,未发现 GDF-9 基因突变或 FMR1 前突变。在 1 例患者中发现了 BMP15 基因的新型杂合突变 c.406G>C(V136L)。在 COV434 细胞中转染后,与野生型相比,BMP15 变体的荧光素酶活性显著降低。
POI 是一种具有多种健康影响的多因素疾病。自身免疫和遗传是最常见的病因。我们鉴定并表征了一种新型 BMP15 突变,为这一复杂疾病的分子基础提供了更多的解释。